Evidence map›Paper›PMID 28706899›Full record

ReviewAnnals of translational medicine2017

Intra-abdominal manifestations of pleural mesothelioma.

Paul H Sugarbaker

Open access · hybridAbstract readReview
In one paragraph

Review in Annals of translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Paul H SugarbakerCenter for Gastrointestinal Malignancies, Program in Peritoneal Surface Oncology, MedStar Washington Hospital Center, Washington, DC, USA.
MedStar Washington Hospital Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant pleural mesothelioma is a disease characterized by persistent and progressive disease within the hemithorax. However, after aggressive local-regional treatment using surgery, regional chemotherapy, radiation therapy, and systemic chemotherapy, metastases outside of the pleural space may become the chief obstacle to long-term survival. One possible direction of cancer dissemination is direct extension through the hemidiaphragm into the peritoneal space by the disease itself or as a result of diaphragm resection. In those patients who have isolated progression of disease within the peritoneal space, evaluation of their clinical condition using prognostic indicators is essential. Patients with a limited extent of disease and favorable radiologic findings by CT should be considered for cytoreductive surgery using peritonectomy procedures and perioperative combined intraperitoneal and systemic chemotherapy. Although few patients with pleural to peritoneal disease extension have been treated, some favorable long-term results suggest that selected patients should be thoroughly evaluated for disease control within the abdominal and pelvic space.

Indexed as

concerning radiologic featurescytoreductive surgerydiaphragm resectionhyperthermic intraperitoneal chemotherapy (HIPEC)intraperitoneal chemotherapyMalignant peritoneal mesotheliomaperitonectomysarcomatoid mesothelioma

Identifiers

PMID28706899
PMCPMC5497119
OpenAlexW2588581140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.